Somewhat Positive News Coverage Somewhat Unlikely to Impact Sierra Oncology (SRRA) Share Price
News articles about Sierra Oncology (NASDAQ:SRRA) have been trending somewhat positive recently, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sierra Oncology earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.6359001420206 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Sierra Oncology (SRRA) opened at $3.16 on Friday. Sierra Oncology has a 1 year low of $1.10 and a 1 year high of $3.41.
Sierra Oncology (NASDAQ:SRRA) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.03. equities analysts predict that Sierra Oncology will post -0.85 EPS for the current fiscal year.
A number of equities analysts have commented on SRRA shares. ValuEngine raised Sierra Oncology from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Jefferies Group raised Sierra Oncology from a “hold” rating to a “buy” rating in a research note on Monday, October 23rd. Finally, Zacks Investment Research cut Sierra Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $4.00.
Sierra Oncology Company Profile
Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.